Whether thyroid nodules in pregnant women are more susceptible to malignancy than those in non-pregnant women is uncertain, as there are no population-based studies in this area. Evaluation of thyroid nodules in pregnant patients is the same as in non-pregnant women, except that radionuclide scanning is contraindicated. In addition, if a diagnosis of DTC is made after FNA biopsy of a thyroid nodule in a pregnant woman, the procedure should be postponed until after delivery, which does not affect the postoperative outcome. FNA should be performed in pregnant patients with thyroid nodules with normal thyroid function and hypothyroidism. In patients with suppressed serum TSH levels that persist after the third trimester, FNA should be postponed until after secretion and cessation of breastfeeding, when a radionuclide scan may also be performed to evaluate nodule function. If FNA cytology results continue to suggest PTC, surgical treatment should be considered. However, there is no consensus on whether surgery should be performed during pregnancy or after delivery. In the case of surgery during pregnancy, it should be performed before the mid-24th week of pregnancy in order to minimize the risk of miscarriage. PTC found during pregnancy is similar in aggressiveness to PTC in patients of the same age group who are not pregnant women. Furthermore, a retrospective study of pregnant women with DTC found no difference in postoperative nodal recurrence and survival between surgical treatment during pregnancy or after delivery, and no significant impact on prognosis if treatment was delayed for less than 1 year from the date of thyroid cancer diagnosis. Another recent study noted a higher incidence of postoperative complications in pregnant women who underwent surgery compared to those who were not pregnant. Some experts recommend that pregnant women with suspicious FNA results or confirmed PTC receive thyroid hormone suppression therapy during pregnancy if surgery is delayed until after delivery. 1. Nodules with cytology suggestive of PTC found early in pregnancy should be closely monitored by ultrasound, and if they grow significantly by 24 weeks of gestation, surgery should be considered immediately. However, if there is no significant change by mid-pregnancy or if thyroid cancer is diagnosed in mid-pregnancy, surgery can be delayed until after delivery. For patients with severe disease, surgery can be performed in the middle of pregnancy. 2. For pregnant women with suspicious FNA results or confirmed PTC, levothyroxine treatment can be considered to maintain TSH at 0.1-1 mU/L.